Clinical Report: FDA Approves Treg Cell Therapy

Overview

The FDA has approved Tregzi, the first regulatory T-cell-based immunotherapy, for improving chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation. The approval was based on the PRECISION-T trial, which demonstrated significant improvements in chronic GVHD-free survival rates.

Background

Chronic graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic stem cell transplantation, impacting patient survival and quality of life. Current treatments for GVHD are limited and often involve corticosteroids, which can have substantial side effects. The introduction of Tregzi represents a novel therapeutic approach aimed at enhancing immune tolerance and reducing the incidence of chronic GVHD.

Data Highlights

Key Findings

• Tregzi is composed of donor-derived regulatory T cells, conventional T cells, and hematopoietic stem and progenitor cells.
• The PRECISION-T trial enrolled 187 adult patients with blood cancers.
• The primary endpoint was chronic GVHD-free survival, measured over 2 years.
• Patients treated with Tregzi had a 1-year chronic GVHD-free survival rate of 78% compared to 38% for standard transplant.
• Serious chronic GVHD occurred in 13% of Tregzi patients versus 44% in the control group.
• No severe infusion reactions or graft failures were reported during the study.

Clinical Implications

The approval of Tregzi provides a new option for patients at risk of chronic GVHD following stem cell transplantation. Clinicians may consider this therapy to improve patient outcomes in this high-risk population.

Conclusion

Tregzi's approval marks a significant advancement in the management of chronic GVHD, potentially improving survival rates and quality of life for patients undergoing allogeneic hematopoietic stem cell transplantation.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
2. The ASCO Post — FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma
3. The ASCO Post — FDA Approves CAR T-Cell Therapy for Adults With Certain Types of Large B-Cell Lymphoma
4. dana-farber — The Next Wave of Immune Cell Therapy
5. Bone Marrow Transplantation — Treg Cell Therapy as a Treatment for Graft-versus-Host Disease
6. FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma
7. FDA Approves CAR T-Cell Therapy for Adults With Certain Types of Large B-Cell Lymphoma
8. The Next Wave of Immune Cell Therapy
9. Treg Cell Therapy as a Treatment for Graft-versus-Host Disease
10. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update
11. FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies | FDA
12. FDA approves axatilimab-csfr for chronic graft-versus-host disease | FDA